A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012

Journal of Cancer Research and Clinical Oncology
Georg MaschmeyerDietger Niederwieser

Abstract

There is a paucity of data on the incidence of neuroendocrine tumors (NET) outside pulmonary primaries and on treatment modalities applied to patients with NET in clinical practice. Only very little therapeutic progress has been made with respect to response and overall survival, particularly among patients with poorly differentiated, WHO grade 3 neuroendocrine carcinomas (G3-NEC). We sought to document the incidence and treatment modalities in patients with NET/NEC within a period of 2 years. We conducted a retrospective data analysis using a simple documentation file to be completed in written form or electronically, including localization, WHO grading, treatment modalities, and specific therapeutic regimens applied. Primary lung cancer was excluded. The time period to be covered was 2010 through 2012. Individual patient data such as names or age were not documented, so that no ethics committee approval was required. Ten different hospital- or practice-based institutions contributed their data. One to 35 patients were documented per institution, summing up to 149 patients with 154 tumor localizations. Midgut (n = 46), foregut (n = 42), hindgut (n = 17), lung (n = 9), bladder (n = 8), unknown primary (n = 11), and other includ...Continue Reading

References

Feb 13, 2001·Critical Reviews in Oncology/hematology·E Mitry, P Rougier
Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthF Anthony Greco
Sep 13, 2006·Virchows Archiv : an International Journal of Pathology·G RindiUNKNOWN European Neuroendocrine Tumor Society (ENETS)
Aug 4, 2007·Virchows Archiv : an International Journal of Pathology·G RindiB Wiedenmann
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoDouglas B Evans
Sep 25, 2009·Neuroendocrinology·Ursula PloeckingerUNKNOWN representatives of 21 German NET Centers
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YaoBertram Wiedenmann
Jul 29, 2010·Pancreas·Jonathan R StrosbergUNKNOWN North American Neuroendocrine Tumor Society (NANETS)
Feb 12, 2011·Cancer Metastasis Reviews·Kjell Oberg, Daniel Castellano
Aug 3, 2011·Nature Reviews. Endocrinology·Guido Rindi, Bertram Wiedenmann
Sep 13, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H SorbyeU Knigge
Sep 14, 2012·TheScientificWorldJournal·Ingrid H OlsenSeppo W Langer
Feb 9, 2013·Seminars in Oncology·James Smith, Diane Reidy-Lagunes
Nov 2, 2013·Rare Tumors·Rodrigo Ramella MunhozRachel Riechelmann

❮ Previous
Next ❯

Citations

Sep 4, 2020·World Journal of Gastrointestinal Oncology·Yong-Jun YuShi-Wu Zhang
Dec 11, 2020·The Oncologist·Elettra MerolaRachel van Leeuwaarde

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.